Low-Carb Diet Therapy for Type 2 Diabetes Mellitus with Diabetic Gastroparesis and Occasional Liver Dysfunction
Keywords:
Type 2 diabetes (T2D), Diabetic gastroparesis (DG), Gastric emptying (GE), Functional dyspepsia (FD), Low carbohydrate diet (LCD)Abstract
Diabetes mellitus (DM) has wider neurological complications. They include upper gastrointestinal (GI) symptoms, impaired motility, impaired gastric emptying (GE) and diabetic gastroparesis (DG), which are usually found. The patient was a 64-year-old man with type 2 diabetes (T2D) for 22-years. The patient weighed 74 kg with body mass index (BMI) 23.6 kg/m2, hemoglobin A1C (HbA1c) 9.2%, ankle brachial index (ABI) 1.19/1.23, AST 25 U/L(7-38), ALT 23 U/L(4-44), GGT 48 U/L(<86), Chest X-P normal, and electrocardiogram (ECG) negative. When the patient was treated with low carbohydrate diet (LCD), a significant reduction in body weight and HbA1c was observed. Abdominal computerized tomography (CT) revealed multiple gall stone, dilated common bile duct and impaired GE, indicating DG. For endoscopic examination, much food residue was found in the stomach due to DG after 13 hours fasting. Treatment for DG was initiated by mosapride citrate hydrate. During clinical progress, occasional liver dysfunction was observed twice associated with elevation of AST 196 U/L, GGT 373 U/L and without symptoms, indicating cholestasis-type dysfunction. Some possible triggers may be involved in these episodes, such as gall stone, enlarged volume of stomach due to DG, overeating, overdrinking, and other factors. This impressive report will hopefully become a reference for developing diabetic practice and research.
References
International Diabetes Federation (IDF). IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019. Bando H et al
American Diabetes Association (ADA). 10. Cardiovascular dis-ease and risk management: Standards of medical care in diabetesd 2021. Diabetes Care. 2021; 44(Suppl.1): S125-S150. doi: 10.2337/ dc21-S010
Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pel-licano R. Management of dyspepsia and gastroparesis in patients with diabetes. A clinical point of view in the year 2021. J Clin Med. 2021; 10(6): 1313. doi: 10.3390/jcm10061313
Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: Synopsis of the 2020 American Diabetes Associ-ation’s Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020; 173: 813-821. doi: 10.7326/M20-2470
Atkins RC. Dr. Atkins’ New Diet Revolution. New Delhi, India: Harper Collins Publishers India Limited; 2009.
Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al. Weight loss with a low-carbohydrate, mediter-ranean, or low-fat diet. N Engl J Med. 2008; 359: 229-241. doi: 10.1056/NEJMoa0708681
Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base. Nutrition. 2015; 31(1): 1-13. doi: 10.1016/j.nut.2014.06.011
Ebe K, Ebe Y, Yokota S, Matsumoto T, Hashimoto M, Sakai Y, et al. Low Carbohydrate diet (LCD) treated for three cases as diabetic diet therapy. Kyoto Medical Association Journal. 2004; 51: 125-129.
Muneta T, Kagaguchi E, Nagai Y, Matsumoto M, Ebe K, Wata-nabe H, et al. Ketone body elevation in placenta, umbilical cord, newborn and mother in normal delivery. Glycat Stress Res. 2016; 3 (3): 133-140. doi: 10.24659/gsr.3.3_133
Bando H, Ebe K, Hashimoto M, Bando M, Muneta T. A trial of analysis method for insulin secretion response to carbohydrate loading. Edel J Biomed Res Rev. 2020; 2: 20-23. doi: 10.33805/2690- 2613.111
Ebe K, Bando H, Muneta T, Bando M, Yonei Y. Remarkable improvement of glucose variability by Sodium–glucose cotrans-porter 2 (SGLT2) inhibitors using continuous glucose monitor-ing (CGM). Diabetes Case Rep. 2019; 4: 1. doi: 10.4172/2572- 5629.1000139
Hayashi K, Yasuoka T, Bando H, Miki K, Nakagawa M, Zushi T, et al. Useful Xultophy for older diabetic with various problems. SunText Rev Med Clin Res. 2021; 2(2): 126. doi: 10.51737/2766- 4813.2021.027
Yasuoka T, Hayashi K, Bando H, Miki K, Kamoto A, Ha-mai M, et al. Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient. Endocrinol Metab Int J. 2021; 9(2): 32-36. doi: 10.15406/emij.2021.09.00305
Kato Y, Bando H, Yamashita H, Yada S, Tokuhara S, Tokuhara H, et al. Seasonal changes in HbA1c values from young to elderly diabetic patients. J Diabetes Metab Disord Control. 2019; 6(3): 89-92. doi: 10.15406/jdmdc.2019.06.00187
Bando H. Useful tips for actual low carbohydrate diet (LCD) with super-, standard- and petit-LCD methods. EC Nutrition. 2020; 15(5): 1-4.
Nakamura T, Bando H, Kawashima T, Dobashi M, Narita A. Weight reduction by effective protocol of diet and exercise. J Diab Obes Metab. 2019; 2(1): 106.
Gotfried J, Priest S, Schey R. Diabetes and the small intestine. Curr Treat Options Gastroenterol. 2017; 15: 490-507. doi: 10.1007/ s11938-017-0155-x
Bonetto S, Gruden G, Beccuti G, Ferro A, Saracco GM, Pel-licano R. Management of dyspepsia and gastroparesis in patients with diabetes. A clinical point of view in the year 2021. J Clin Med. 2021; 10(6): 1313. doi: 10.3390/jcm10061313
Bharucha AE, Kudva YC, Prichard DO. Diabetic gastropare-sis. Endocr Rev. 2019; 40: 1318-1352. doi: 10.1210/er.2018-00161
Pasricha PJ, Grover M, Yates KP, Abell TL, Bernard CE, Koch KL, et al. Functional dyspepsia and gastroparesis in tertiary care are interchangeable syndromes with common clinical and pathological features. Gastroenterology. 2021; 160(6): 2006-2017. doi: 10.1053/j.gastro.2021.01.230 Submit your article to this journal | https://openventio.org/submit-manuscript/
Choung RS, Locke GR III, Schleck CD, Zinsmeister AR, Melton LJ III, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012; 107: 82-88. doi: 10.1038/ajg.2011.310
Tack J, van den Houte K, Carbone F. Gastroduodenal motility disorders. Curr Opin Gastroenterol. 2018; 34: 428-435. doi: 10.1097/ MOG.0000000000000473
Durazzo M, Lupi G, Cicerchia F, Ferro A, Barutta F, Beccuti G, et al. Extra-esophageal presentation of gastroesophageal re-flux disease: 2020 Update. J Clin Med. 2020; 9: 2559. doi: 10.3390/ jcm9082559
Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: Management of dys-pepsia. Am J Gastroenterol. 2017; 112: 988-1013. doi: 10.1038/ ajg.2017.154
JinM, Mo Y, Ye K, Chen M, Liu Y, He C. Efficacy of sero-tonin receptor agonists in the treatment of functional dyspep-sia: A meta-analysis. Arch Med Sci. 2019; 15: 23-32. doi: 10.5114/ aoms.2017.69234
Uchida M, Yamato S, Shimizu K, Amano T, Ariga H. Dual role of mosapride citrate hydrate on the gastric emptying evalu-ated by the breath test in conscious rats. J Pharmacol Sci. 2013; 121(4): 282-287. doi: 10.1254/jphs.12237fp
Nishizawa T, Mori K, Yoshida S, Ebinuma H, Toyoshima O, Suzuki H. Additional mosapride to proton pump inhibitor for gastroesophageal reflux disease: A meta-analysis. J Clin Med. 2020; 9(9): 2705. doi: 10.3390/jcm9092705
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
